Back to search results

Evaluating New Eye Imaging Technology for Glaucoma and Macular Disease

This study is looking at new ways to check for and keep track of eye diseases like glaucoma and macular degeneration. Researchers are testing a scanning device called Optical Coherence Tomography (OCT) and comparing its results to other eye imaging and vision tests already approved by the FDA. The goal is to see if OCT can help doctors diagnose eye diseases earlier and monitor their progression. You might be able to join if you are 18 or older, are healthy, or have conditions like age-related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, or glaucoma. The study is also looking at how glaucoma progresses over up to five years. The current status of this study is unclear.

Study design
This is an observational study with a planned enrollment of 5000 participants. It includes different sub-studies to evaluate the effectiveness and reliability of OCT technology.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to see evidence of glaucoma progression for up to five years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00286637

Novel Glaucoma Diagnostics

Recruiting
Not specifiedAges 18+Observational
Wills Eye
~5,000 participants
Updated 2024-08-15 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants who Show Evidence of Glaucoma Progression
Measured over Up to Year 5

Conditions

Glaucoma
Macular Disease

Explore related trials

Alzheimer's DiseaseCentral Serous ChorioretinopathyDiabetic RetinopathyGlaucomaMacular DegenerationMild cognitive disorder

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Joel S Schumann, MD · STUDY_CHAIR · Wills Eye Hospital

Who to contact

Taylor Harwood
[email protected]
215-928-3197
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to provide informed consent and to understand the study procedures
Healthy volunteers
Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects
(AD Sub-Study ONLY): Subjects diagnosed with AD or MCI.

Exclusion

Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma.
Strabismus, nystagmus, or any condition that prevents fixation.
Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality
History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.

What this trial measures

  • Number of Participants who Show Evidence of Glaucoma ProgressionUp to Year 5

    The purpose of this research is to Participants who show evidence of glaucoma progression are classified as "progressors." Participants who show evidence of glaucoma progression are classified as "progressors."